Literature DB >> 18832250

A new class of anti-HIV therapy and new challenges.

Raphael Dolin.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18832250     DOI: 10.1056/NEJMe0806598

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 2.  Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Authors:  Caroline M Perry
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

Review 3.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

4.  Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa.

Authors:  Joakim Esbjörnsson; Fredrik Månsson; Wilma Martínez-Arias; Elzbieta Vincic; Antonio J Biague; Zacarias J da Silva; Eva Maria Fenyö; Hans Norrgren; Patrik Medstrand
Journal:  Retrovirology       Date:  2010-03-22       Impact factor: 4.602

5.  Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.

Authors:  S Reuter; P Braken; B Jensen; S Sierra-Aragon; M Oette; M Balduin; R Kaiser; D Häussinger
Journal:  Eur J Med Res       Date:  2010-06-28       Impact factor: 2.175

Review 6.  Targeting chemokines for acute lymphoblastic leukemia therapy.

Authors:  Zixi Hong; Zimeng Wei; Tian Xie; Lin Fu; Jiaxing Sun; Fuling Zhou; Muhammad Jamal; Qiuping Zhang; Liang Shao
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.